Anavex Life Sciences Announces Initiation of First-in-Human Phase 1 Study of ANAVEX®3-71 (AF710B)GlobeNewsWire • 05/21/20
Anavex Life Sciences' (AVXL) CEO Christopher Missling on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/08/20
Anavex Life Sciences Announces Publication of Clinical Data for ANAVEX®2-73 (blarcamesine) in Alzheimer’s DiseaseGlobeNewsWire • 04/23/20
Anavex Life Sciences (AVXL) Stock Moves -0.38%: What You Should KnowZacks Investment Research • 04/03/20
All You Need to Know About Anavex Life Sciences (AVXL) Rating Upgrade to Strong BuyZacks Investment Research • 02/17/20
Anavex Life Sciences' (AVXL) CEO Christopher Missling on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/07/20
Anavex Life Sciences Announces Fast Track Designation Granted by U.S. FDA for ANAVEX®2-73 (blarcamesine) Clinical Development Program for the Treatment of Rett SyndromeGlobeNewsWire • 02/03/20
Anavex Life Sciences Announces Achievement of Enrollment Target for the ANAVEX®2-73 (blarcamesine) Phase 2 Parkinson’s Disease Dementia (PDD) Clinical TrialGlobeNewsWire • 01/27/20
Anavex Life Sciences (AVXL) Moves to Strong Buy: Rationale Behind the UpgradeZacks Investment Research • 01/14/20
Anavex Life Sciences Issued New U.S. Patent for ANAVEX®2-73 Treatment of Neurodevelopmental Disorders including Rett Syndrome and Multiple SclerosisGlobeNewsWire • 01/08/20
Anavex Life Sciences Corp.'s (AVXL) CEO Christopher Missling on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 12/16/19
Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment of Rett SyndromeGlobeNewsWire • 11/14/19
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett SyndromeGlobeNewsWire • 11/06/19
Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s DiseaseGlobeNewsWire • 10/09/19